File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Enteropathy-associated T-cell lymphoma: Clinical and histological findings from the international peripheral T-Cell lymphoma project
  • Basic View
  • Metadata View
  • XML View
TitleEnteropathy-associated T-cell lymphoma: Clinical and histological findings from the international peripheral T-Cell lymphoma project
 
AuthorsDelabie, J10
Holte, H10
Vose, JM9
Ullrich, F9
Jaffe, ES1
Savage, KJ11
Connors, JM11
Rimsza, L12
Harris, NL2
MüllerHermelink, K7
Rüdiger, T5
Coiffier, B16
Gascoyne, RD11
Berger, F16
Tobinai, K8
Au, WY6
Liang, R6
Montserrat, E15
Hochberg, EP4
Pileri, S13
Federico, M3
Nathwani, B14
Armitage, JO9
Weisenburger, DD9
 
Issue Date2011
 
PublisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
 
CitationBlood, 2011, v. 118 n. 1, p. 148-155 [How to Cite?]
DOI: http://dx.doi.org/10.1182/blood-2011-02-335216
 
AbstractFew large, international series of enteropathy-associated T-cell lymphoma (EATL) have been reported. We studied a cohort of 62 patients with EATL among 1153 patients with peripheral T-cell or natural killer (NK) - cell lymphoma from 22 centers worldwide. The diagnosis was made by a consensus panel of 4 expert hematopathologists using World Health Organization (WHO) criteria. Clinical correlations and survival analyses were performed. EATL comprised 5.4% of all lymphomas in the study and was most common in Europe (9.1%), followed by North America (5.8%) and Asia (1.9%). EATL type 1 was more common (66%) than type 2 (34%), and was especially frequent in Europe (79%). A clinical diagnosis of celiac sprue was made in 32.2% of the patients and was associated with both EATL type 1 and type 2. The median overall survival was only 10 months, and the median failure-free survival was only 6 months. The International Prognostic Index (IPI) was not as good a predictor of survival as the Prognostic Index for Peripheral T-Cell Lymphoma (PIT). Clinical sprue predicted for adverse survival independently of the PIT. Neither EATL subtype nor other biologic parameters accurately predicted survival. Our study confirms the poor prognosis of patients with EATL and the need for improved treatment options.
 
ISSN0006-4971
2013 Impact Factor: 9.775
 
DOIhttp://dx.doi.org/10.1182/blood-2011-02-335216
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorDelabie, J
 
dc.contributor.authorHolte, H
 
dc.contributor.authorVose, JM
 
dc.contributor.authorUllrich, F
 
dc.contributor.authorJaffe, ES
 
dc.contributor.authorSavage, KJ
 
dc.contributor.authorConnors, JM
 
dc.contributor.authorRimsza, L
 
dc.contributor.authorHarris, NL
 
dc.contributor.authorMüllerHermelink, K
 
dc.contributor.authorRüdiger, T
 
dc.contributor.authorCoiffier, B
 
dc.contributor.authorGascoyne, RD
 
dc.contributor.authorBerger, F
 
dc.contributor.authorTobinai, K
 
dc.contributor.authorAu, WY
 
dc.contributor.authorLiang, R
 
dc.contributor.authorMontserrat, E
 
dc.contributor.authorHochberg, EP
 
dc.contributor.authorPileri, S
 
dc.contributor.authorFederico, M
 
dc.contributor.authorNathwani, B
 
dc.contributor.authorArmitage, JO
 
dc.contributor.authorWeisenburger, DD
 
dc.date.accessioned2012-09-05T05:30:44Z
 
dc.date.available2012-09-05T05:30:44Z
 
dc.date.issued2011
 
dc.description.abstractFew large, international series of enteropathy-associated T-cell lymphoma (EATL) have been reported. We studied a cohort of 62 patients with EATL among 1153 patients with peripheral T-cell or natural killer (NK) - cell lymphoma from 22 centers worldwide. The diagnosis was made by a consensus panel of 4 expert hematopathologists using World Health Organization (WHO) criteria. Clinical correlations and survival analyses were performed. EATL comprised 5.4% of all lymphomas in the study and was most common in Europe (9.1%), followed by North America (5.8%) and Asia (1.9%). EATL type 1 was more common (66%) than type 2 (34%), and was especially frequent in Europe (79%). A clinical diagnosis of celiac sprue was made in 32.2% of the patients and was associated with both EATL type 1 and type 2. The median overall survival was only 10 months, and the median failure-free survival was only 6 months. The International Prognostic Index (IPI) was not as good a predictor of survival as the Prognostic Index for Peripheral T-Cell Lymphoma (PIT). Clinical sprue predicted for adverse survival independently of the PIT. Neither EATL subtype nor other biologic parameters accurately predicted survival. Our study confirms the poor prognosis of patients with EATL and the need for improved treatment options.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationBlood, 2011, v. 118 n. 1, p. 148-155 [How to Cite?]
DOI: http://dx.doi.org/10.1182/blood-2011-02-335216
 
dc.identifier.citeulike9564667
 
dc.identifier.doihttp://dx.doi.org/10.1182/blood-2011-02-335216
 
dc.identifier.epage155
 
dc.identifier.issn0006-4971
2013 Impact Factor: 9.775
 
dc.identifier.issue1
 
dc.identifier.pmid21566094
 
dc.identifier.scopuseid_2-s2.0-79960117770
 
dc.identifier.spage148
 
dc.identifier.urihttp://hdl.handle.net/10722/163384
 
dc.identifier.volume118
 
dc.languageeng
 
dc.publisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
 
dc.publisher.placeUnited States
 
dc.relation.ispartofBlood
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAdult
 
dc.subject.meshAged
 
dc.subject.meshAged, 80 And Over
 
dc.subject.meshCeliac Disease - Classification - Mortality - Pathology
 
dc.subject.meshCohort Studies
 
dc.subject.meshConsensus
 
dc.subject.meshEnteropathy-Associated T-Cell Lymphoma - Classification - Mortality - Pathology
 
dc.subject.meshFemale
 
dc.subject.meshHumans
 
dc.subject.meshInternationality
 
dc.subject.meshKiller Cells, Natural - Pathology
 
dc.subject.meshMale
 
dc.subject.meshMiddle Aged
 
dc.subject.meshPredictive Value Of Tests
 
dc.subject.meshPrognosis
 
dc.subject.meshSurvival Analysis
 
dc.subject.meshT-Lymphocytes - Pathology
 
dc.subject.meshWorld Health Organization
 
dc.titleEnteropathy-associated T-cell lymphoma: Clinical and histological findings from the international peripheral T-Cell lymphoma project
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Delabie, J</contributor.author>
<contributor.author>Holte, H</contributor.author>
<contributor.author>Vose, JM</contributor.author>
<contributor.author>Ullrich, F</contributor.author>
<contributor.author>Jaffe, ES</contributor.author>
<contributor.author>Savage, KJ</contributor.author>
<contributor.author>Connors, JM</contributor.author>
<contributor.author>Rimsza, L</contributor.author>
<contributor.author>Harris, NL</contributor.author>
<contributor.author>M&#252;llerHermelink, K</contributor.author>
<contributor.author>R&#252;diger, T</contributor.author>
<contributor.author>Coiffier, B</contributor.author>
<contributor.author>Gascoyne, RD</contributor.author>
<contributor.author>Berger, F</contributor.author>
<contributor.author>Tobinai, K</contributor.author>
<contributor.author>Au, WY</contributor.author>
<contributor.author>Liang, R</contributor.author>
<contributor.author>Montserrat, E</contributor.author>
<contributor.author>Hochberg, EP</contributor.author>
<contributor.author>Pileri, S</contributor.author>
<contributor.author>Federico, M</contributor.author>
<contributor.author>Nathwani, B</contributor.author>
<contributor.author>Armitage, JO</contributor.author>
<contributor.author>Weisenburger, DD</contributor.author>
<date.accessioned>2012-09-05T05:30:44Z</date.accessioned>
<date.available>2012-09-05T05:30:44Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Blood, 2011, v. 118 n. 1, p. 148-155</identifier.citation>
<identifier.issn>0006-4971</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/163384</identifier.uri>
<description.abstract>Few large, international series of enteropathy-associated T-cell lymphoma (EATL) have been reported. We studied a cohort of 62 patients with EATL among 1153 patients with peripheral T-cell or natural killer (NK) - cell lymphoma from 22 centers worldwide. The diagnosis was made by a consensus panel of 4 expert hematopathologists using World Health Organization (WHO) criteria. Clinical correlations and survival analyses were performed. EATL comprised 5.4% of all lymphomas in the study and was most common in Europe (9.1%), followed by North America (5.8%) and Asia (1.9%). EATL type 1 was more common (66%) than type 2 (34%), and was especially frequent in Europe (79%). A clinical diagnosis of celiac sprue was made in 32.2% of the patients and was associated with both EATL type 1 and type 2. The median overall survival was only 10 months, and the median failure-free survival was only 6 months. The International Prognostic Index (IPI) was not as good a predictor of survival as the Prognostic Index for Peripheral T-Cell Lymphoma (PIT). Clinical sprue predicted for adverse survival independently of the PIT. Neither EATL subtype nor other biologic parameters accurately predicted survival. Our study confirms the poor prognosis of patients with EATL and the need for improved treatment options.</description.abstract>
<language>eng</language>
<publisher>American Society of Hematology. The Journal&apos;s web site is located at http://bloodjournal.hematologylibrary.org/</publisher>
<relation.ispartof>Blood</relation.ispartof>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Aged</subject.mesh>
<subject.mesh>Aged, 80 And Over</subject.mesh>
<subject.mesh>Celiac Disease - Classification - Mortality - Pathology</subject.mesh>
<subject.mesh>Cohort Studies</subject.mesh>
<subject.mesh>Consensus</subject.mesh>
<subject.mesh>Enteropathy-Associated T-Cell Lymphoma - Classification - Mortality - Pathology</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Internationality</subject.mesh>
<subject.mesh>Killer Cells, Natural - Pathology</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Predictive Value Of Tests</subject.mesh>
<subject.mesh>Prognosis</subject.mesh>
<subject.mesh>Survival Analysis</subject.mesh>
<subject.mesh>T-Lymphocytes - Pathology</subject.mesh>
<subject.mesh>World Health Organization</subject.mesh>
<title>Enteropathy-associated T-cell lymphoma: Clinical and histological findings from the international peripheral T-Cell lymphoma project</title>
<type>Article</type>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1182/blood-2011-02-335216</identifier.doi>
<identifier.pmid>21566094</identifier.pmid>
<identifier.scopus>eid_2-s2.0-79960117770</identifier.scopus>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-79960117770&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>118</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>148</identifier.spage>
<identifier.epage>155</identifier.epage>
<publisher.place>United States</publisher.place>
<identifier.citeulike>9564667</identifier.citeulike>
</item>
Author Affiliations
  1. National Cancer Institute
  2. Massachusetts General Hospital
  3. Università degli Studi di Modena e Reggio Emilia
  4. Massachusetts General Hospital Cancer Center
  5. Städtischen Klinikum Karlsruhe
  6. The University of Hong Kong
  7. Julius-Maximilians-Universität Würzburg
  8. National Cancer Center Hospital
  9. University of Nebraska Medical Center
  10. Rikshospitalet-Radiumhospitalet HF
  11. British Columbia Cancer Agency
  12. University of Arizona
  13. Alma Mater Studiorum Università di Bologna
  14. Keck School of Medicine of USC
  15. Universitat de Barcelona
  16. Centre Hospitalier Lyon-Sud